OMCL Falls 20.1% in a Month as Booking and Margin Risks Build
Omnicell (OMCL) shares fell 20.1% over four weeks. The company reported Q2 2026 adjusted EPS of $0.94, up 108.9% y/y, and revenue of $312.2M, up 7.4%. Omnicell raised 2026 non-GAAP EPS to $2.15-$2.30 and EBITDA to $175-$185M, but expects $6M incremental memory-chip costs, weaker product bookings ($425-$560M) and lower annual recurring revenue ($660-$680M).
How this was made
The 30-second read
Why it matters
The company’s updated outlook contains a split message: higher full-year profit guidance alongside weaker booking visibility, reduced annual recurring revenue guidance, and a larger-than-expected 2H 2026 memory-chip cost headwind.
Market read
Traders may reprice OMCL around the updated 2026 guidance mix, especially the magnitude of 2H memory-chip costs and the reduced annual recurring revenue outlook.
What to watch
The tariff refund is explicitly non-recurring, but the article does not quantify how much of the margin pressure is offset by pricing, mix, or cost-down actions beyond the stated bps headwinds.
Background
OMCL shares are down 20.1% over four weeks as investors weigh whether the pullback improves risk-reward versus persistent execution and margin risks.
Ticker impact
Omnicell raised 2026 non-GAAP EPS and EBITDA guidance but flagged higher 2H 2026 memory-chip costs and weaker booking/ARR visibility.
Choppy to bearish bias likely, with traders focusing on margin and bookings timing rather than the raised profit outlook.
The article’s newest decision-relevant facts are the incremental $6M memory-chip cost expectation, gross margin headwind (50 bps consolidated, 80 bps product), reduced annual recurring revenue guidance, and widened product bookings range due to slower transaction timing.
Market effects
Signals potential cost inflation and margin pressure risk for medical device automation and dispensing system vendors with hardware-linked components.
No specific regional catalyst described.
Memory-chip supply-demand imbalance is cited as a cost driver, implying broader semiconductor-driven input cost sensitivity.
Counterpoint
The raised 2026 EPS and EBITDA guidance, plus a forward sales multiple below its 5-year median, could attract dip-buyers if bookings eventually convert to deployments.
Key entities
- public_companyOmnicell, Inc.
Subject of the article; updated 2026 guidance includes higher profit outlook but weaker bookings/ARR visibility and margin headwinds from memory-chip costs.
- public_companyBecton, Dickinson and Company
Competitor mentioned for BD Pyxis systems; no new news disclosed in the article.
- public_companyMcKesson Corporation
Competitor mentioned for pharmacy automation technologies; no new news disclosed in the article.
